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Abstract
Association between susceptibility to 
polycystic ovary syndrome and the 
genetic polymorphisms of aryl 
hydrocarbon receptor repressor, 
glutathione-S-transferase M1 and 
glutathione-S-transferase T1 genes
CHUNG YOUN KYUNG
Medicine/Obstetrics & Gynecology 
The Graduate School 
Seoul National University
Objective: It is well known that genetic polymorphism is also involved 
in the onset of polycystic ovary syndrome (PCOS), but currently there 
is no study about the polymorphism of detoxification enzymes in PCOS 
patients. We investigated the effect of genotype on clinical features of 
PCOS by comparing the distribution of aryl hydrocarbon receptor 
repressor (AhRR), glutathione-S-transferase M1 (GSTM1) and 
glutathione-S-transferase T1 (GSTT1) gene polymorphisms and 
phenotypes 
Design: The study was a case-control study including 478 women with 
PCOS and 376 women without PCOS from the Seoul National University 
Hospital and the Seoul National University Hospital Healthcare System.
Materials and Methods: Genomic DNA was extracted from peripheral 
blood. Genotyping of the AhRR codon 185 was performed by real-time 
PCR analysis on an ABI Prism 7000 Sequence Detection System. GSTM1 
and GSTT1 genotyping for gene deletions were carried out by multiplex 
PCR analysis.
Results: There was a trend for an association of C/G+G/G genotypes 
with the patients with PCOS (p=0.06). But there was no difference in 
the genotype distribution of GSTM1 or GSTT1. Nevertheless, analyzing 
AhRR and GSTT1 together, we found that patients with high-risk 
genotypes at both loci have increased in patients with PCOS compared 
with controls (p=0.03, OR=1.54, CI=1.04-2.29). When classification of 
PCOS patients according by phenotype, there were significant 
differences in the combined G-allele genotype and GSTT1 null 
genotypes between no hirsutism group and controls (p=0.02). The 
combined GSTM1/GSTT1 null genotypes were also a trend for an 
association with PCOS.
Conclusions: The AhRR codon 185, GSTM1 and GSTT1 mutant variants 
individually are not associated with the pathophysiology of PCOS. 
However, combined G allele of AhRR codon 185 and GSTT1 null 
genotype or combined GSTT1/GSTM1 null genotypes could be associated 
with pathophysiologic aberrance involved in PCOS.
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I. Introduction
  Polycystic ovary syndrome (PCOS) is one of the common endocrine 
disorders and affects from 2-27% of reproductive age women 1-3. Three 
definitions are most commonly cited about PCOS, National Institute of 
Child Health and Human Development (NICHD) criteria (1990), the 
European Society for Human Reproduction and Embryology and 
American Society for Reproductive Medicine (ESHRE/ASRM or 
Rotterdam) criteria (2003) and Androgen Excess Society (AES) criteria 
(2006). All three definitions emphasized the importance of 
hyperandrogenism and ovulation disorders 4,5 and of these three, the 
Rotterdam criteria is the most widely used.
PCOS is also associated with several long-term health consequences 
such as infertility, hirsutism, diabetes, cardiovascular disease, and breast 
cancer. But the exact causes of PCOS are not fully explained. Some 
recent studies have explained that genetic factors play an important 
role in the etiology and pathogenesis of PCOS 6,7, some studies 
suggested that the environmental factors have been related to the 
pathogenesis and prevalence of PCOS 8-10.
   
  Endocrine disruptors or endocrine-disrupting chemicals (EDCs) are 
known as ‘environmental hormones' because they disrupt normal 
hormone synthesis, secretion, transport or function in the body and 
affect the endocrine system of the body and have negative effects 
7,11-15. Importantly, many EDCs show a non-monotonic dose-response 
curves, and low-dose exposure may influence certain endocrine system 
in the body 16. EDCs have been reported to be associated with 
adipocyte formation or obesity, and these suggest the association 
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between EDCs and metabolic disorders 14,17. Due to increase in 
precocious puberty, high expectations are being placed on the role of 
EDCs acting on female hormones 13. The effects of endocrine disruptors 
on human body are related to the detoxification process, especially 
detoxification enzyme gene polymorphisms such as Aryl hydrocarbon 
receptor repressor (AhRR), glutathione-S-transferase M1 (GSTM1) and 
glutathione-S- transferase T1 (GSTT1) have been reported that it can 
be a major mediator between the endocrine disruptor and reproductive 
disease, and the association between endometriosis and the AhRR, 
GSTM1, and GSTT1 polymorphisms has been reported in Human 
Reproduction 18. 
   
  Glutathione S-transferase (GST) is a typical enzyme of phase II 
conjugation enzymes which are function to inactivate environmental 
toxins. GST is involved in the metabolism of environmental carcinogens 
such as the enzymes of the cytochrome p-450 family and have several 
isozymes which metabolize specific substrates or respond to duplicate 
substrates 19-21. Eight classes of mammalian cytosolic GSTs are currently 
reported, such as alpha (A), mu (M), kappa (K), omega (O), pi (P), 
sigma (S), theta (T), and zeta (Z) 22.
  The expression of GSTs enzymes is mainly influenced by the genetic 
polymorphisms of the GSTs genes. It is reported that the GST genotype 
differs according to race, and the relative risk for disease varies with 
race. A number of GSTs are expressed as polymorphisms, and the first 
two GSTs reported for polymorphisms were GSTT1 and GSTM1. These 
polymorphisms have been reported to vary by race, GSTM1 is 
homozygously deleted in about 50% and GSTT1 in 20% of caucasian 
individuals in central Europe 23. Haase et al. reported that GSTM1 null 
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genotype accounted for about 50% in European, Japanese, and 
Caucasian populations and about 25% of Afro-Americans, whereas 
GSTT1 null genotype is common in Asian populations and are not well 
documented in Europeans and other ethnic groups 24. And based on 
meta–analysis of case-control studies, it were reported that the GSTT1 
null genotype increased significantly the risk of chronic myeloid 
leukemia in nine Caucasian, East Asian, and Indian populations, but not 
to East Asian people. These studies suggest that antioxidant status and 
degree of DNA damage of GSTM1 and GSTT1 genotypes vary 
depending on race 25. According to studies for race-specific GST 
polymorphisms, the GSTT1 null genotype appeared 50-60% in Asians 
and 10-20% in Europeans and Americans and the GSTM1 null genotype 
accounted for 50-60% of Europeans, Japanese and Caucasian, while 
India and the United States were 25% respectively 24. In the 
GST-related studies conducted on Koreans, the GSTT1 null genotype 
appeared 50-60% and GSTM1 null genotype accounted for 48-55% in 
Koreans 18,26,27. GSTM1 and GSTT1 are known to be polymorphisms in 
humans and both of them have null alleles resulting from gene deletion 
28. The null genotypes of GSTM1 and GSTT1 are less likely to be able 
to remove activated carcinogens, resulting in a higher risk of cancer. 
Meta-analyses have revealed that the deletion of either GSTM1 or 
GSTT1 is associated with a significant increased risk of hypertension, 
coronary heart disease and several cancers 27,29-31, and also the 
deletions associated with reproductive disorders such as endometriosis or 
male infertility 18,32,33. But currently there is no study about the 
polymorphisms of GSTM1 or GSTT1 in PCOS patients.
  The aryl hydrocarbon receptor (AhR) is a nuclear receptor 
transcription factor present in the cytoplasm and the superfamily of 
- 4 -
basic Helix-Loop-Helix/ Per-ARNT-Sim (bHLH/PAS) proteins 34,35. When 
AhR bounds to dioxin ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), they form complexes and move to the nucleus, where they 
combine with AhR nuclear translocator (ARNT) to form a dimer. 
Activation of these pathways may cause endocrine abnormality, 
immune-toxicity or carcinogenesis. AhR target genes encode for 
drug-metabolizing enzymes, such as cytochrome P450 (CYP) 34,35. The 
AhR is ligand-dependent transcription factor localized to cytoplasm that 
regulates gene expression, immune response, cell cycle control, and cell 
differentiation 36-39.
  The AhRR is a member of growing superfamily, is a bHLH/PAS
protein, located in chromosome 5p15.3 40 and regulates AhR signaling 
by repressing AhR-dependent gene expression. The N-terminal part of 
the AhRR protein has high structural similarities with AhR, by contrast, 
its C-terminal has no structural similarities with AhR 35,37. AhRR acts as 
a suppressor AhR–dependent gene expression and modulate AhR-gene 
expression by competitive binding to ARNT 40. There are three general 
forms in the AhRR gene; c.565C>G (Pro185Ala, rs2292596); c.1462G>A 
(Arg 473 Gln, rs769781351); and c.5303NA>T (NA, rs10078). The G allele 
polymorphism has caused by exchange of proline (Pro) 185 to alanine 
(Ala) 185 amino acid 41. The G-allele of AhRR has been reported to be 
associated with a variety of diseases including endometriosis, male 
infertility, germ cell cancer, and oral cancer 41,42.
  The expression of AhRR is high in testis, lung, ovary, spleen and 
pancreas in adults, whereas expression is low in all tissues in fetuses 43. 
Also AhR and AhRR are all expressed in the female reproductive 
system and could change expression under specific pathologic conditions 
44. Reduced expression of AhRR has been observed in many types of 
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cancerous human tissue, including breast cancer, prostate cancer, 
hepatocellular carcinoma, and others 40,45,46, and also in reproductive 
abnormality such as the endometriosis 18,41. But as far as we know, no 
previous reports on the expression status of AhRR in polycystic ovarian 
syndrome.
  I compared the distribution of AhRR, GSTM1 and GSTT1 gene 
polymorphisms and phenotypes associated with the detoxification process 
of exogenous endocrine disruptors in PCOS and normal control women 
to determine the effect of genotype on clinical features of PCOS. The 
primary goal of the present study was to explore the association 
between AhRR polymorphism and the risk of PCOS in a Korean 
population and also tried to determine whether the genetic 
polymorphisms of GSTM1 and GSTT1 were associated with PCOS in the 
same population.
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II. Materials and Methods
Subjects
  There were recruited 478 PCOS patients using the Rotterdam criteria 
and 376 age-matched controls visited the Seoul National University 
Hospital Healthcare System Gangnam Center. Their ages ranged from 
18–40 years in the PCOS patient group and control group and they all 
agreed to participate in the investigation of PCOS genetic 
predisposition. 
  The diagnosis of PCOS was based on the 2003 Rotterdam criteria. 
When a patient meets, PCOS was diagnosed at least two of the 
following must be present: 1) oligo-or anovulation, 2) hyperandrogenism 
(either clinical or biochemical), and 3) a polycystic ovary (PCO) as 
determined by ultrasonography. Oligomenorrhoea was defined as less 
than eight periods per year or cycles longer than 35 days, and 
amenorrhea was defined as no menstruation for more than 3 months 
without pregnancy. Clinical hyperandrogenism was defined by a 
modified Ferriman and Gallwey score (mF-G score) of six or greater 47 
and biochemical hyperandrogenism was defined as total testosterone (T) 
>0.68 ng/ml, free T>1.72 pg/ml, and free androgen index (FAI) 48. PCO 
was defined as the presence of 12 or more follicles measuring 2–9 mm 
in diameter, or an increased ovarian volume (exceeds 10 cm3). The 
exclusion of other related disorders and the definition of 
oligo-ovulation, anovulation, and clinical and biochemical 
hyperandrogenism have been previously reported 49,50.
  A total of 376 age-matched premenopausal women served as control 
subjects visited the Seoul National University Hospital Healthcare System 
Gangnam Center. They visited as an individual need for a check-up or 
a part of group check-up for work with no specific health problems, 
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and these women did not have any of the three items apply the same 
three diagnostic items of Rotterdam criteria. The Institutional Review 
Board of Seoul National University approved the study (IRB number: 
H-0501-140-008).
Clinical and Biochemical Measurements
  Clinical factors, such as height, body weight, waist circumference 
(WC), and blood pressure (BP), were measured from all women in both 
groups. Body mass index (BMI) was calculated as body mass (kg) divided 
by the square of the body heigh (㎡), and WC was measured by a 
trained person with the measuring tape placed horizontally at the 
smallest diameter between the costal margin and the iliac crest while 
the participant gently exhaled. All subjects in both groups had taken no 
medications, such as oral contraceptives, lipid-lowering agents, and 
insulin sensitizers in the last 6 months. The subjects were evaluated for 
serum hormonal or metabolic parameters with the use of a previously 
described protocol 50.
Genomic DNA analysis
  Blood was drawn from each participants who fasted overnight, and 
genomic DNA was extracted with the Wizard DNA Purification Kit 
(Promega, Madison, WI, USA). 
  The AhRR polymorphism was genotyped using real-time polymerase 
chain reaction (PCR) analysis on an ABI PRISM® 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA). The reaction mixture 
contained 10㎕ of the 2x Taq-Man Universal PCR Master Mix and 25 ng 
of DNA. The PCR cycling conditions consisted of a 2-minute cycle at 
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50℃ and a 10-minute cycle at 95℃, followed by 40 cycles of 95℃ for 
15 seconds and 60℃ for 1 minute. Distilled water was used as a 
negative PCR control in each amplification. Each 20 ml PCR reaction 
contained 10 pmol of forward primer 5’-AGACGGATGTTATGCACCAGA
A-3’, 10 pmol of reverse primer 5’-AGAGGCAGCGATGTGTTATGG
-3’, 4 pmol of C-allele probe 5’-(FAM)-TGGGCAGCCCCCCGCC-(TAM
RA)-3’, 4 pmol of G-allele probe 5’-(VIC)-TGGGCAGGCCCCGCC-(TA
MRA)-3’, 10 ml of 2X TaqMan Universal PCR Master Mix (Applied 
Biosystems) and 25 ng DNA. The PCR cycling conditions consisted of 
one 2 min cycle at 50 ℃ and one 10 min cycle at 95 ℃, followed by 
40 cycles of 95 ℃ for 15 s and 60 ℃ for 1 min. Distilled water was 
used as a negative PCR control in each amplification. The PCR primers 
for the GSTM1 and the GSTT1 polymorphisms were 
5’-GAACTCCCTGAAAAGCTAAAGC-3’(forward), 5‘-GTTGGGCTCAAA
TATACGGTGG-3’(reverse) (Bioneer, Seoul, Korea), 5’-TTCCTTACTGG
TCCTCACATCTC-3’ (forward), and 5’-TCACCGGATCATGGCCAGCA
-3’(reverse) (Bioneer) (Table 1). 
  The subjects assessed for serum hormonal and metabolic parameters 
with the use of a previously described protocol 18 (Figure 1).
Statistical analysis
  Power calculations were performed with the QUANTO v.1.2.4 (log-
additive model) software (http://hydra.usc.edu/gxe/). Based on the 
specified sample size (377 patients with PCOS and 386 controls), the 
power was calculated to detect an allelic odds ratio of 1.5 at an α 
value of 0.05.
  Normal distributions were achieved using a natural logarithmic or 
square root transformation and Continuous parameters were compared 
- 9 -
using Student’s t-test. In the controls, the genotype distribution was 
examined for significant departures from the Hardy–Weinberg 
equilibrium using a chi square goodness-of-fit test. To evaluate the 
association between the patient–control status and each individual SNP, 
logistic regression analyses were used to calculate the odds ratios (ORs) 
and 95% confidence intervals (CIs). In all the analyses, the homozygote 
of wild-type allele was defined as the reference category. Differences 
in phenotypic variables and differences in including diagnostic criteria 
among PCOS patients were analyzed by 1-way ANOVA followed by the 
least significant difference test for post hoc comparisons. In the 
patients with PCOS, the multi-variate linear regression model was used 
for comparing the HOMA-IR, HOMA βcell, and 2h 75-g insulin levels 
according to each individual genotype. All the data analyses were 
performed using SPSS software (version 17.0; SPSS Inc. Chicago, IL, 
USA), and the significance was accepted for two-sided P-values < 0.05.
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Figure 1. Agarose gel electrophoresis of the multiplex PCR for 
genotyping GSTM1 and GSTT1. β-globulin gene was used as an 
internal positive control. Line a: molecular marker (100 bp DNA ladder); 
line b:GSTM1 null/GSTT1 present; line c:GSTM1 null/GSTT1 null; line d: 




  A total of 478 women with PCOS and 376 age-matched controls were 
recruited in the current study. Genotypic distributions of the codon 185 
of AhRR genes were in Hardy–Weinberg equilibrium in both groups.
Analysis of AhRR genes polymorphism frequency
  The genotype distribution of codon 185 polymorphism in the AhRR 
gene in two groups was as follows: CC/CG/GG rates were 37.2% /48.5% 
/14.2% in the PCOS group and CC/CG/GG rates were 43.6% /44.7% 
/11.7% in control group. There was a tendency to an association of 
C/G+G/G genotypes with PCOS patients (62.8% versus 56.4%, p=0.06, 
OR: 1.14, 95% CI: 0.91-1.43), which did not show statistical significance 
in two groups (Table 2). 
Analysis of GSTM1 and GSTT1 polymorphism frequency
  The proportion of null mutation at GSTT1 also tended to increase in 
patients with PCOS, but there was no statistically significant difference 
(52.3% versus 48.9%, p=0.33, OR: 1.14, 95% CI: 0.87-1.49). The 
proportion of null mutation at GSTM1 showed a slightly different 
pattern, which did not also reach statistical significance in both groups. 
In contrary to GSTT1 result, the proportion of null mutation at GSTM1 
in PCOS patients was slightly decreased than in control group (47.3% 
versus 51.3%, p=0.24, OR: 0.85, 95% CI: 0.65-1.11) (Table 3). 
Analyzing AhRR and GSTT1/GSTM1 genes polymorphism 
together
  The combined G-allele genotype and GSTT1 null genotypes were 
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statistically significant higher in PCOS patients compared to controls 
(31.6% versus 27.4%, p=0.03, OR=1.54, CI=1.04-2.29) (Table 4). Analyzing 
AhRR and GSTM1 together, it was also tended to increase in patients 
with PCOS, but there was no statistically significant difference (28.9% 
versus 30.1%, p=0.51, OR: 1.14, 95% CI: 0.77-1.68) (Table 4).
Analyzing AhRR and GSTT1/GSTM1 genes polymorphism 
together according to diagnostic criteria or phenotypic 
variables
  There was no statistically significant difference in polymorphism of 
genotype according to the diagnostic criteria in the classification based 
on PCOS diagnostic criteria (the 2003 ARSM/ESHRE consensus meeting 
guideline). But, classification of PCOS patients according to phenotype 
showed similar pattern to previous results. PCOS patients group was 
divided in to two groups according to the phenotype (H-core <6 and 
H-score ≥6). Then, the genotype distributions of codon 185 
polymorphism in the AhRR gene, GSTT1 and GSTM1 were compared in 
the control group. By ANOVA analysis, there were significant 
differences in the combined G-allele genotype and GSTT1 null 
genotypes among three groups. Further analysis (Tukey) showed 
statistical differences between no hirsutism group and controls (p=0.02) 
(Table 6). There are no statistical differences in a single genotype 
distribution of AhRR, GSTT1 or GSTM1 in three groups.
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Table 2. Distribution of codon 185 polymorphism in the AhRR gene in 






P value OR (95% CI)
AhRR gene 
polymorphism
    　     
CC (%) 178 (37.3%) 164 (43.6%)     
CG (%) 232 (48.5%) 168 (44.7%) 0.10b 1.27 (0.95-1.70)
GG (%) 68 (14.2%) 44 (11.7%) 0.11b 1.42 (0.92-2.20)  
      
CC (%) 178 (37.2%) 164 (43.6%)     
non-CC 300 (62.8%) 212 (56.4%) 0.06 a
1.30 
(0.99-1.72)
C allele 410 (57.7%) 332 (61.0%)   
G allele 300 (42.3 %) 212 (39.0%) 0.25 a 1.14 (0.91-1.43)
a evaluated by chi-square test in comparison with the control group
b evaluated by logistic regression analysis in comparison with the control group
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Table 3. Prevalence of homozygosity for the GSTM1 and GSTT1 null 
mutations in PCOS patients and controls
  PCOS (n=478)
Control 
(n=376)
P value OR (95% CI)
  GSTM1
Present 252 (52.7%) 184 (48.7%)
0.85 
(0.65-1.11)
Null 226 (47.3%) 193 (51.3%) 0.24a
  GSTT1
Present 228 (47.7%) 192 (51.1%)
1.14 
(0.87-1.49)
Null 250 (52.3%) 184 (48.9%) 0.33a
a
evaluated by chi-square test in comparison with the control group
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Table 4. Risk of PCOS according to the number of possible high risk 



















    
              







              










evaluated by logistic regression analysis in comparison with the control group
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Table 5. Risk of PCOS according to the number of possible high risk 



















    
              









      














  P value a
  AhRR   NS
  GSTT1   NS
  GSTM1   NS
  AhRR + GSTT1   0.02 H-score<6 vs. control*
  AhRR + GSTM   NS
  CC vs non-CC   NS
  GSTT1+GSTM1   NS
Table 6. Distribution of codon 185 polymorphism in the AhRR gene and 
prevalence of homozygosity for the GSTM1 and GSTT1 null mutations in 
controls according to H-score
a evaluated by 1-way ANOVA in comparison with the control group
* post hoc tests run by Tukey's HSD
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IV. Discussions
  The goal of this study was to evaluate the association between AhRR 
polymorphism and the risk of PCOS and to determine whether the 
genetic polymorphisms of GSTM1 and GSTT1 are associated with 
susceptibility to PCOS in a Korean population. There was no significant 
difference in a single genotype distribution of AhRR, GSTT1 or GSTM1 
in PCOS patients compared to controls. But, combined two risk factors, 
such as the non-CC genotypes/ GSTT1 null mutation have been 
associated with PCOS comparing to controls. There were no differences 
in polymorphism of genotype according to the diagnostic criteria in the 
classification based on PCOS diagnostic criteria. Only in PCOS groups 
without hirsutism showed significant statistical differences in the 
combined G-allele genotype and GSTT1 null genotypes comparing to 
controls. 
  In PCOS, one of the most common reproductive endocrine diseases of 
reproductive-age women, the association with endocrine disruptor has 
been reported. Takeuchi et al. have shown that Bisphenol A (BPA) 
concentrations were increased in women diagnosed with PCOS and 
testosterone levels were increased as BPA clearance decreased 51. Also, 
Galazis et al. reported that the expression level of GSTM3 was 
increased compared with controls in PCOS omental fat and Glutathione 
S-transferase P (GSTP) protein expression was increased in the 
endometrial tissues of PCOS patients diagnosed with endometrial cancer 
52,53. Finally, it can be assumed that environmental factors are involved 
in the pathophysiology of PCOS. In recent years, Yang, et al. found 
increased expression of p,p′-dichlorodiphenyldichloro ethylene (p,p′
-DDE) and polycyclic aromatic hydrocarbons in serum with PCOS 54.
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  Previous studies have demonstrated the associations between EDCs 
and PCOS but there are limitations with the small sample size and 
there is no study about the polymorphism of detoxification enzymes in 
PCOS patients. The AhR pathway is known to be critical for cellular 
events, especially for those caused by several environmental chemicals 
such as TCDD. Upon binding to TCDD, they form complexes and 
translocates into the nucleus, where they combine with ARNT to form 
a dimer. The AhR/ARNT dimer recognizes a DNA enhancer element 
sequence, designated xenobiotic responsive element (XRE), located in 
the promoter region of CYP1A1 gene, causing gene expression 54,55. 
AhR is a ligand-dependent transcription factor present in ovarian 
tissues and AhR plays an important role in the regulation of ovarian 
follicular growth and secretion of hormones 56. Kim at el. have shown 
that detoxification enzyme gene polymorphisms such as AhRR, GSTM1 
and GSTT1 have a major mediator between the EDCs and 
endometriosis 18. That study has shown that a single genetic 
polymorphism involving AhRR, GSTM1 or GSTT1 exhibits a marginal 
effect, but can confer a significant increase in the risk of 
endometriosis if the putative high-risk genotypes at the two loci are 
combined (P=0.015, OR:1.86, 95% CI: 1.13–3.06).
  GST is the primary cellular defense mechanism against reactive 
oxygen species as phase II detoxification enzymes found mainly in the 
cytosol. Cytosolic GSTs of mammals were originally classified into Mu, 
Kappa, Alpha, Pi, accounting for 4% of the total cytosolic proteins 20,57. 
Among these, GSTM1 and GSTT1 genes are mainly polymorphic in 
humans and the null genotypes causing by loss of function mutations 
are resulted in lack of enzyme activity 28,56.
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  GSTT1 and GSTM1 differ according to race, and the relative risk for 
disease varies with race. These polymorphisms have been reported to 
vary by race, GSTM1 is homozygously deleted in about 50% and GSTT1 
in 20% of caucasian individuals in central Europe 23. GSTM1 gene 
polymorphism in European, Japanese, and Caucasian populations 
accounted for about 50% of GSTM1 null genotype and about 25% of 
Afro-Americans genotype, whereas GSTT1 null genotypes are common 
in Asian populations 24. The frequencies of the GSTM1 and GSTM1 null 
genotype in this study were similar to other studies in Koreans. The 
GSTM1-null genotype was found in 51.5% and the GSTT1-null genotype 
was found in 50.8% participants (Table 3). 
  Several studies related to the association between the GST isoenzyme 
family and environmental factors in diabetes mellitus (DM) have been 
reported in recently. In a recent report, there are findings the 
combined, both GSTM1/GSTT1 null genotypes are to be considered 
among the polymorphic genetic risk factors for type 2 DM. The null 
GSTM1 and GSTT1 alleles did not reveal an increased frequency but, 
the combined GSTM1/GSTT1 null genotypes were statistically 
significantly higher in DM patients compared to control subjects 
(p=0.0021, OR=0.313, CI=0.149-0.655) 58. Previous studies did not show 
an association between AhRR polymorphism and some disease such as 
endometriosis 59 or lung cancer 60. But some studies showed that the 
negative feedback effect of AhRR on the dioxin for the C (pro) allele 
is a significant association with reduced male fertility 61,62 and the GG 
allele of AhRR has a negative result on the sexual system. 
  As shown in table 2 and table 4, a single genetic polymorphism 
involving AhRR, single GSTM1 and GSTT1 mutant variants exhibit no 
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significantly associated with PCOS compared to controls. But the 
combined high-risk genotypes at the two loci, such as AhRR (G 
allele)/GSTT1 null genotype or GSTM1/GSTT1 null genotypes were 
significant higher in PCOS women compared to controls. Our results 
come in agreement with other studies in different endocrine diseases 
11,18,48,58,63,64.
  
  In conclusion, a single genetic polymorphism involving AhRR, GSTM1 
and GSTT1 mutant variants individually are not associated with PCOS 
but combined the high-risk genotypes could be considered genetic risk 
factor in PCOS. Our data suggest that combined genetic polymorphisms 
in the several candidate genes might be involved in the pathogenesis 
of PCOS. In future studies, more accurate results might be obtained by 
calibrating these variables in PCOS patients and controls. Although the 
present study has these limitations, to the best of our knowledge this is 
the first reported study about the polymorphism of detoxification 
enzymes in PCOS patients.
- 23 -
V. References
1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, 
Davies MJ. The prevalence of polycystic ovary syndrome in a 
community sample assessed under contrasting diagnostic criteria. 
Human reproduction. Feb 2010;25(2):544-551.
2. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of 
polycystic ovary syndrome among premenopausal women with 
type 2 diabetes. Diabetes care. 2001;24(6):1050-1052.
3. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of 
polycystic ovary syndrome in unselected women from southern 
China. European Journal of Obstetrics & Gynecology and 
Reproductive Biology. 2008;139(1):59-64.
4. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining 
polycystic ovary syndrome as a predominantly hyperandrogenic 
syndrome: an androgen excess society guideline. The Journal of 
Clinical Endocrinology & Metabolism. 2006;91(11):4237-4245.
5. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a 
reappraisal. Elsevier; 2005.
6. Lim S, Norman R, Davies M, Moran L. The effect of obesity on 
polycystic ovary syndrome: a systematic review and 
meta‐analysis. Obesity Reviews. 2013;14(2):95-109.
7. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of 
genes and environment in the etiology of PCOS. Endocrine. 
2006;30(1):19-26.
8. Amato P, Simpson JL. The genetics of polycystic ovary 
syndrome. Best Practice & Research Clinical Obstetrics & 
Gynaecology. 2004;18(5):707-718.
- 24 -
9. Guerrero-Bosagna CM, Skinner MK. Environmental epigenetics 
and phytoestrogen/phytochemical exposures. The Journal of 
steroid biochemistry and molecular biology. 2014;139:270-276.
10. Panidis D, Tziomalos K, Papadakis E, et al. The role of orlistat 
combined with lifestyle changes in the management of 
overweight and obese patients with polycystic ovary syndrome. 
Clinical endocrinology. 2014;80(3):432-438.
11. Caserta D, Maranghi L, Mantovani A, Marci R, Maranghi F, 
Moscarini M. Impact of endocrine disruptor chemicals in 
gynaecology. Human reproduction update. 2007;14(1):59-72.
12. Latini G, Scoditti E, Verrotti A, De Felice C, Massaro M. 
Peroxisome proliferator-activated receptors as mediators of 
phthalate-induced effects in the male and female reproductive 
tract: epidemiological and experimental evidence. PPAR research. 
2008;2008.
13. Gregoraszczuk EL, Ptak A. Endocrine-Disrupting Chemicals: 
Some Actions of POPs on Female Reproduction. International 
journal of endocrinology. 2013;2013:828532.
14. Darbre PD. Endocrine disruptors and obesity. Current obesity 
reports. 2017;6(1):18-27.
15. Barrett ES, Sobolewski M. Polycystic ovary syndrome: do 
endocrine disrupting chemicals play a role? Paper presented at: 
Seminars in reproductive medicine2014.
16. Vandenberg LN, Colborn T, Hayes TB, et al. Hormones and 
endocrine-disrupting chemicals: low-dose effects and 
nonmonotonic dose responses. Endocrine reviews. 
2012;33(3):378-455.
- 25 -
17. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental 
estrogens and obesity. Molecular and cellular endocrinology. May 
25 2009;304(1-2):84-89.
18. Kim SH, Choi YM, Lee GH, et al. Association between 
susceptibility to advanced stage endometriosis and the genetic 
polymorphisms of aryl hydrocarbon receptor repressor and 
glutathione-S-transferase T1 genes. Human reproduction. Jul 
2007;22(7):1866-1870.
19. Ketterer B. Protective role of glutathione and glutathione 
transferases in mutagenesis and carcinogenesis. Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis. 
1988;202(2):343-361.
20. Oakley A. Glutathione transferases: a structural perspective. 
Drug metabolism reviews. 2011;43(2):138-151.
21. Mannervik B. The isoenzymes of glutathione transferase. 
Advances in enzymology and related areas of molecular biology. 
1985;57:357-417.
22. Bessa SS, Ali EM, Hamdy SM. The role of glutathione 
S-transferase M1 and T1 gene polymorphisms and oxidative 
stress-related parameters in Egyptian patients with essential 
hypertension. European Journal of Internal Medicine. 
2009;20(6):625-630.
23. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. 
Annu. Rev. Pharmacol. Toxicol. 2005;45:51-88.
24. Haase D, Binder C, Bünger J, et al. Increased risk for 
therapy-associated hematologic malignancies in patients with 
carcinoma of the breast and combined homozygous gene 
deletions of glutathione transferases M1 and T1. Leukemia 
research. 2002;26(3):249-254.
- 26 -
25. Zintzaras E. Glutathione S-transferase M1 and T1 genes and 
susceptibility to chronic myeloid leukemia: a meta-analysis. 
Genetic testing and molecular biomarkers. 2009;13(6):791-797.
26. Cho H-J, Lee S-Y, Ki C-S, Kim J-W. GSTM1, GSTT1 and 
GSTP1 polymorphisms in the Korean population. Journal of 
Korean medical science. 2005;20(6):1089-1092.
27. Han J-H, Lee H-J, Kim T-S, Kang M-H. The effect of 
glutathione S-transferase M1 and T1 polymorphisms on blood 
pressure, blood glucose, and lipid profiles following the 
supplementation of kale (Brassica oleracea acephala) juice in 
South Korean subclinical hypertensive patients. Nutrition research 
and practice. 2015;9(1):49-56.
28. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione 
S-transferase theta (GSTT1): cDNA cloning and the 
characterization of a genetic polymorphism. Biochemical Journal. 
1994;300(1):271-276.
29. Qiu L-X, Yuan H, Yu K-D, et al. Glutathione S-transferase M1 
polymorphism and breast cancer susceptibility: a meta-analysis 
involving 46,281 subjects. Breast cancer research and treatment. 
2010;121(3):703-708.
30. Liao C, Cao Y, Wu L, Huang J, Gao F. An updating 
meta-analysis of the glutathione S-transferase T1 polymorphisms 
and colorectal cancer risk: a HuGE review. International journal 
of colorectal disease. 2010;25(1):25-37.
31. Wang B, Huang G, Wang D, et al. Null genotypes of GSTM1 
and GSTT1 contribute to hepatocellular carcinoma risk: evidence 
from an updated meta-analysis. Journal of hepatology. 
2010;53(3):508-518.
- 27 -
32. Zhu H, Bao J, Liu S, Chen Q, Shen H. Null genotypes of 
GSTM1 and GSTT1 and endometriosis risk: a meta-analysis of 25 
case-control studies. PloS one. 2014;9(9):e106761.
33. Wu W, Lu J, Tang Q, et al. GSTM1 and GSTT1 null 
polymorphisms and male infertility risk: an updated meta-analysis 
encompassing 6934 subjects. Scientific reports. 2013;3:2258.
34. Abel J, Haarmann-Stemmann T. An introduction to the 
molecular basics of aryl hydrocarbon receptor biology. Biological 
chemistry. 2010;391(11):1235-1248.
35. Denison MS, Nagy SR. Activation of the aryl hydrocarbon 
receptor by structurally diverse exogenous and endogenous 
chemicals. Annual review of pharmacology and toxicology. 
2003;43(1):309-334.
36. Guo S-W, Simsa P, Kyama CM, et al. Reassessing the evidence 
for the link between dioxin and endometriosis: from molecular 
biology to clinical epidemiology. Molecular human reproduction. 
2009;15(10):609-624.
37. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y. Identification of 
a novel mechanism of regulation of Ah (dioxin) receptor 
function. Genes & development. 1999;13(1):20-25.
38. Urban JD, Budinsky RA, Rowlands JC. Single nucleotide 
polymorphisms in the human aryl hydrocarbon receptor nuclear 
translocator (ARNT) gene. Drug metabolism and 
pharmacokinetics. 2011;26(6):637-645.
39. Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous 
ligands of aryl hydrocarbon receptor: current state of art. 
Current drug metabolism. 2011;12(2):198-212.
40. Zudaire E, Cuesta N, Murty V, et al. The aryl hydrocarbon 
receptor repressor is a putative tumor suppressor gene in 
- 28 -
multiple human cancers. The Journal of clinical investigation. 
2008;118(2):640-650.
41. Zheng N-n, Bi Y-p, Zheng Y, Zheng R-h. Meta-analysis of the 
association of AhR Arg554Lys, AhRR Pro185Ala, and ARNT 
Val189Val polymorphisms and endometriosis risk in Asians. 
Journal of assisted reproduction and genetics. 
2015;32(7):1135-1144.
42. Mohammad‐Hasani A, Hosseinzadeh Colagar A, Fallah A. 
Association of the human aryl hydrocarbon receptor repressor 
(AhRR)‐c. 565C> G transversion with male infertility: A 
case‐control study from Iran. Journal of cellular biochemistry. 
2018.
43. Yamamoto J, Ihara K, Nakayama H, et al. Characteristic 
expression of aryl hydrocarbon receptor repressor gene in 
human tissues: organ-specific distribution and variable induction 
patterns in mononuclear cells. Life sciences. 
2004;74(8):1039-1049.
44. Khorram O, Garthwaite M, Golos T. Uterine and ovarian aryl 
hydrocarbon receptor (AHR) and aryl hydrocarbon receptor 
nuclear translocator (ARNT) mRNA expression in benign and 
malignant gynaecological conditions. Molecular human 
reproduction. 2002;8(1):75-80.
45. Monick MM, Beach SR, Plume J, et al. Coordinated changes in 
AHRR methylation in lymphoblasts and pulmonary macrophages 
from smokers. American Journal of Medical Genetics Part B: 
Neuropsychiatric Genetics. 2012;159(2):141-151.
46. Sanada N, Gotoh Y, Shimazawa R, Klinge CM, Kizu R. 
Repression of Activated Aryl Hydrocarbon Receptor–Induced 
Transcriptional Activation by 5α-Dihydrotestosterone in Human 
- 29 -
Prostate Cancer LNCaP and Human Breast Cancer T47D Cells. 
Journal of pharmacological sciences. 2009;109(3):380-387.
47. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: 
implications, etiology, and management. American journal of 
obstetrics and gynecology. Aug 01 1981;140(7):815-830.
48. Chae SJ, Kim JJ, Choi YM, et al. Clinical and biochemical 
characteristics of polycystic ovary syndrome in Korean women. 
Human reproduction. Aug 2008;23(8):1924-1931.
49. Kim JJ, Chae SJ, Choi YM, et al. Assessment of hirsutism 
among Korean women: results of a randomly selected sample of 
women seeking pre-employment physical check-up. Human 
reproduction. Jan 2011;26(1):214-220.
50. Kim JJ, Choi YM, Cho YM, et al. Polycystic ovary syndrome is 
not associated with polymorphisms of the TCF7L2, CDKAL1, 
HHEX, KCNJ11, FTO and SLC30A8 genes. Clinical endocrinology. 
Sep 2012;77(3):439-445.
51. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. 
Positive relationship between androgen and the endocrine 
disruptor, bisphenol A, in normal women and women with 
ovarian dysfunction. Endocrine journal. Apr 2004;51(2):165-169.
52. Corton M, Botella-Carretero JI, Lopez JA, et al. Proteomic 
analysis of human omental adipose tissue in the polycystic ovary 
syndrome using two-dimensional difference gel electrophoresis 
and mass spectrometry. Human reproduction. Mar 
2008;23(3):651-661.
53. Galazis N, Pang YL, Galazi M, Haoula Z, Layfield R, Atiomo W. 
Proteomic biomarkers of endometrial cancer risk in women with 
polycystic ovary syndrome: a systematic review and biomarker 
database integration. Gynecological endocrinology : the official 
- 30 -
journal of the International Society of Gynecological 
Endocrinology. Jul 2013;29(7):638-644.
54. Yang Q, Zhao Y, Qiu X, Zhang C, Li R, Qiao J. Association of 
serum levels of typical organic pollutants with polycystic ovary 
syndrome (PCOS): a case–control study. Human reproduction. 
2015;30(8):1964-1973.
55. Fujita H, Kosaki R, Yoshihashi H, et al. Characterization of the 
aryl hydrocarbon receptor repressor gene and association of its 
Pro185Ala polymorphism with micropenis. Teratology. 
2002;65(1):10-18.
56. Hernandez-Ochoa I, Barnett-Ringgold KR, Dehlinger SL, et al. 
The ability of the aryl hydrocarbon receptor to regulate ovarian 
follicle growth and estradiol biosynthesis in mice depends on 
stage of sexual maturity. Biology of reproduction. 
2010;83(5):698-706.
57. Haarmann-Stemmann T, Abel J. The arylhydrocarbon receptor 
repressor (AhRR): structure, expression, and function. Biological 
chemistry. 2006;387(9):1195-1199.
58. Sheehan D, Meade G, Foley VM. Structure, function and 
evolution of glutathione transferases: implications for 
classification of non-mammalian members of an ancient enzyme 
superfamily. Biochemical Journal. 2001;360(1):1-16.
59. Watanabe T, Imoto I, Kosugi Y, et al. Human arylhydrocarbon 
receptor repressor (AHRR) gene: genomic structure and analysis 
of polymorphism in endometriosis. Journal of human genetics. 
2001;46(6):342-346.
60. Cauchi S, Stücker I, Cénée S, Kremers P, Beaune P, 
Massaad-Massade L. Structure and polymorphisms of human aryl 
hydrocarbon receptor repressor (AhRR) gene in a French 
- 31 -
population: relationship with CYP1A1 inducibility and lung cancer. 
Pharmacogenetics and Genomics. 2003;13(6):339-347.
61. Gu A, Ji G, Long Y, et al. Assessment of an association 
between an aryl hydrocarbon receptor gene (AHR) polymorphism 
and risk of male infertility. Toxicological Sciences. 
2011;122(2):415-421.
62. Josarayi GA, Mohammad-Hasani A, Aftabi Y, Moudi E, Colagar 
AH. The AhRR-c. 565C> G transversion may increase total 
antioxidant capacity levels of the seminal plasma in infertile 
men. Environmental Science and Pollution Research. 
2017;24(21):17428-17435.
63. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary 
differences in the expression of the human glutathione 
transferase active on trans-stilbene oxide are due to a gene 
deletion. Proceedings of the National Academy of Sciences. 
1988;85(19):7293-7297.
64. POROJAN MD, Bala C, Ilies R, Catana A, Popp RA, Dumitrascu 
DL. Combined glutathione S transferase M1/T1 null genotypes is 




Aryl hydrocarbon receptor repressor 
glutathione-S-transferase M1, 
glutathione-S-transferase T1 유전자 
다형성과 다낭성 난소증후군과의 
연관관계 규명
목적: 다낭성 난소증후군의 발병에 유전적 소인 역시 관여함은 주지의 
사실이나, 현재 다낭성 난소증후군 환자를 대상으로 detoxification 효소 
유전자 다형성 양상을 본 연구는 전무한 실정이다. 이에 aryl 
hydrocarbon receptor repressor (AhRR), glutathione-S-transferase M1 
(GSTM1), glutathione-S-transferase T1 (GSTT1) 효소 유전자 다형성 
분포를 비교를 통해 유전형이 다낭성 난소증후군의 임상양상에 미치는 
영향을 분석하고자 하였다.
연구방법: 다낭성 난소증후군 유전적 소인규명 연구 참여에 동의한 
다낭성 난소증후군 환자군 478명과 정상대조군 376명의 여성을 대상으로 
하였다. 환자의 말초혈액에서 채취한 혈액에서 유전체 DNA를 
추출하였다. AhRR 유전자 codon 185의 유전형질분석은 실시간 중합효소 
연쇄반응을 통해 수행되었으며 GSTM1과 GSTT1의 유전자 결손에 의한 
유전형질분석은 대용량 중합효소 연쇄반응 분석을 통해 시행하였다.
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결과: 다낭성 난소증후군 환자군에서 정상대조군에 비해 C/G+G/G의 
유전자형에 대한 높은 연관성을 나타내었으나 (p=0.06), 두 군에서 
GSTM1과 GSTT1의 유전자형 분포에 유의한 차이가 없었다. 반면, 
AhRR과 GSTT1의 유전자형을 함께 분석했을 때, 다낭성 난소증후군 
환자군에서 정상대조군에 비해 고위험 유전자형이 유의하게 높게 
관찰되었다 (p=0.03, OR=1.54, CI=1.04-2.29). 또한, 표현형에 따라 다낭성 
난소증후군 환자를 분류했을 때, AhRR과 GSTT1의 고위험 유전자형 
다모증이 없는 다낭성 난소증후군 환자군과 정상대조군에서 유의한 
차이를 보였다 (p=0.02).
결론: The AhRR codon 185, GSTM1 그리고 GSTT1 변이 유전자형은 
각각 개별적으로는 다낭성 난소증후군의 병태생리학에 유의한 연관성을 
보이지 않았다. 그러나 AhRR codon 185의 G 대립유전자와 GSTT1의 
결여 유전자형이, 또는 GSTT1과 GSTM1의 결여 유전자형이 같이 표현될 
때 다낭성 난소증후군의 병태생리학적 이상과 연관될 수 있을 것으로 
사료된다.
주요어: 다낭성 난소증후군, 외인성 내분비 교란화학물질, 유전자 
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